ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,101 to 4,120 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Intervention - Nocturnal Coverage vs Control - Standard of Care: Discharge Home From Hospital317 of 820

314 of 778

-1.7 points

-6.5 to 3.1

1,598NCT01434823

24 Hour Intensivist Coverage in the Medical Intensive Care Unit

Intervention - Nocturnal Coverage vs Control - Standard of Care: Re-admission to the MICU Within 48 Hours32 of 820

21 of 778

1.2 points

-0.6 to 3.0

1,598NCT01434823

24 Hour Intensivist Coverage in the Medical Intensive Care Unit

Intervention - Nocturnal Coverage vs Control - Standard of Care: In-hospital Mortality203 of 820

177 of 778

2.0 points

-2.2 to 6.2

1,598NCT01434823

24 Hour Intensivist Coverage in the Medical Intensive Care Unit

Dabigatran 220mg vs Enoxaparin: Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period17 of 804

31 of 793

-1.8 points

-3.6 to -0.1

1,597NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Intervention Arm vs Usual Care: deaths from any cause142 of 754

130 of 842

3.4 points

-0.3 to 7.1

1,596NCT03832595

Kidney Coordinated Health Management Partnership

Intervention Arm vs Usual Care: serious adverse events18 of 754

21 of 842

-0.1 points

-1.7 to 1.5

1,596NCT03832595

Kidney Coordinated Health Management Partnership

Indacaterol 150 μg vs Tiotropium 18 μg: serious adverse events22 of 794

30 of 799

-1.0 points

-2.8 to 0.8

1,593NCT00900731

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: Mortality24 of 486

23 of 1,106

2.9 points

1.0 to 5.3

1,592NCT05481216

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: deaths from any cause24 of 486

23 of 1,106

2.9 points

1.0 to 5.3

1,592NCT05481216

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: Number of Palliative Discharge1 of 486

0 of 1,106

0.2 points

-0.2 to 1.2

1,592NCT05481216

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: serious adverse events224 of 486

231 of 1,106

25.2 points

20.2 to 30.2

1,592NCT05481216

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

Arm A - Ivermectin 400 vs Arm A - Placebo: Number of Participants With Mortality1 of 817

0 of 774

0.1 points

-0.4 to 0.7

1,591NCT05736861

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

Arm A - Ivermectin 400 vs Arm A - Placebo: Number of Participants With Hospitalization or Death10 of 817

9 of 774

0.1 points

-1.1 to 1.2

1,591NCT05736861

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

Arm A - Ivermectin 400 vs Arm A - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death32 of 817

28 of 774

0.3 points

-1.6 to 2.2

1,591NCT05736861

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

Arm A - Ivermectin 400 vs Arm A - Placebo: deaths from any cause1 of 817

0 of 774

0.1 points

-0.4 to 0.7

1,591NCT05736861

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

Arm A - Ivermectin 400 vs Arm A - Placebo: serious adverse events13 of 817

17 of 774

-0.6 points

-2.1 to 0.8

1,591NCT05736861

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

Toremifene 20mg vs Placebo: serious adverse events117 of 787

137 of 802

-2.2 points

-5.8 to 1.4

1,589NCT00106691

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

Feedback On vs Feedback Off: Survival to Hospital Discharge92 of 815

96 of 771

-1.2 points

-4.4 to 2.0

1,586NCT00539539

Automated Real-time Feedback on CPR Study

Feedback On vs Feedback Off: Rate of ROSC During the Prehospital Resuscitation361 of 815

345 of 771

-0.5 points

-5.3 to 4.4

1,586NCT00539539

Automated Real-time Feedback on CPR Study

Feedback On vs Feedback Off: Pulses Present at ED Arrival.260 of 815

243 of 771

0.4 points

-4.2 to 5.0

1,586NCT00539539

Automated Real-time Feedback on CPR Study

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=206"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=206

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01434823-309f0247",
        "title": "Intervention - Nocturnal Coverage vs Control - Standard of Care: Discharge Home From Hospital",
        "summary": "317 of 820 against 314 of 778; risk difference -1.7 points, 95% interval -6.5 to 3.1; NCT01434823, 24 Hour Intensivist Coverage in the Medical Intensive Care Unit",
        "record": "/library/comparisons/NCT01434823-309f0247",
        "nct_id": "NCT01434823",
        "kind": "outcome",
        "participants": 1598,
        "risk_difference": {
          "value": -0.017013605868706483,
          "lower": -0.06483439683852027,
          "upper": 0.030861397733051438
        },
        "group_1": "317 of 820",
        "group_2": "314 of 778",
        "difference": "-1.7 points",
        "interval": "-6.5 to 3.1",
        "trial_title": "24 Hour Intensivist Coverage in the Medical Intensive Care Unit"
      },
      {
        "id": "NCT01434823-48da2287",
        "title": "Intervention - Nocturnal Coverage vs Control - Standard of Care: Re-admission to the MICU Within 48 Hours",
        "summary": "32 of 820 against 21 of 778; risk difference 1.2 points, 95% interval -0.6 to 3.0; NCT01434823, 24 Hour Intensivist Coverage in the Medical Intensive Care Unit",
        "record": "/library/comparisons/NCT01434823-48da2287",
        "nct_id": "NCT01434823",
        "kind": "outcome",
        "participants": 1598,
        "risk_difference": {
          "value": 0.01203210232616465,
          "lower": -0.005863454730615884,
          "upper": 0.030133169098504282
        },
        "group_1": "32 of 820",
        "group_2": "21 of 778",
        "difference": "1.2 points",
        "interval": "-0.6 to 3.0",
        "trial_title": "24 Hour Intensivist Coverage in the Medical Intensive Care Unit"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=207",
  "request_id": "PHZXO20_zQar1RMl"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?